Press release
Myositis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023
Myositis Pipeline
Key Takeaways from the Myositis Pipeline Report
• DelveInsight's Myositis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myositis treatment.
• The leading companies working in the Myositis Market include Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
• Promising Myositis Pipeline Therapies in the various stages of development includes ABC008, Daxdilimab, BYM338 (Bimagrumab), BYM338, Arimoclomol, Nipocalimab, Glucocorticoids, and others.
• On August 2023, Abcuro Inc. announced a study of Phase 2 & 3 clinical trials for ABC008. A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis.
• On August 2023, Horizon Therapeutics Ireland DAC announced a study of Phase 2 Clinical Trials for Daxdilimab. To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24.
Request a sample and discover the recent advances in Myositis Treatment Drugs @ Myositis Pipeline Report- https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Myositis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Myositis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Myositis clinical trial landscape.
Myositis Overview
The term "myositis" refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest.
Find out more about Myositis Treatment Landscape @ Drugs for Myositis Treatment- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Myositis Emerging Drugs Profile
• Lenabasum: Corbus Pharmaceuticals
• Nipocalimab: Janssen Research & Development, LLC
Myositis Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Myositis. The Myositis companies which have their Myositis drug candidates in the most advanced stage, i.e. phase III include, Corbus Pharmaceuticals.
Learn more about the emerging Myositis Pipeline Therapies @ Myositis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Myositis Pipeline Report
• Coverage- Global
• Allergic Conjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Allergic Conjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Myositis Companies- Corbus Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
• Myositis Pipeline Therapies- ABC008, Daxdilimab, BYM338 (Bimagrumab), BYM338, Arimoclomol, Nipocalimab, Glucocorticoids, and others.
Dive deep into rich insights for new drugs for Myositis Treatment, Visit @ Myositis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Myositis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myositis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Lenabasum: Corbus Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nipocalimab: Janssen Research & Development, LLC
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Myositis Key Companies
18. Myositis Key Products
19. Myositis- Unmet Needs
20. Myositis- Market Drivers and Barriers
21. Myositis- Future Perspectives and Conclusion
22. Myositis Analyst Views
23. Myositis Key Companies
24. Appendix
For further information on the Myositis Pipeline therapeutics, reach out to Myositis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Important Published Links
https://scocial-online.mn.co/posts/46864423
https://akb.tribe.so/post/behcet-s-disease-a-rare-and-chronic-inflammatory-condition-has-long-posed-c--6576dd3288d020256754898b
https://www.sutori.com/en/denny-dones?tab=profile
https://network-96590.mn.co/posts/46865392
https://lean-in-bay-area.mn.co/posts/46865790
https://network-88594.mn.co/posts/46865905
https://decide.mn.co/posts/46866036
https://jomijomig.mn.co/posts/46866708
https://constantlycheeky.mn.co/posts/46867239
https://www.vwvortex.com/members/ybhardwaj.3957496/#about
https://redline-rp.mn.co/posts/46868784
https://forum.eset.com/profile/88964-denny-dones/?tab=field_core_pfield_11
https://en.pinkoi.com/user/gg_116344212900924579142
https://dennydones9.diary.ru/
https://slideslive.com/ewkwsgtt7o?tab=about
https://dennydones.substack.com/p/behcets-syndrome-market-size-in-the?r=33xju7&utm_campaign=post&utm_medium=web
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myositis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 here
News-ID: 3326650 • Views: …
More Releases from DelveInsight Business Research LLP
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 45+ Key Pharma C …
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the…
Muscle Spasticity Clinical Trial Pipeline Appears Robust With 15+ Key Pharma Com …
DelveInsight's "Muscle Spasticity Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Muscle Spasticity pipeline landscape. It covers the Muscle Spasticity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Muscle Spasticity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Brutons Tyrosine Kinase Inhibitors Clinical Trial Pipeline Appears Robust With 3 …
DelveInsight's "Brutons Tyrosine Kinase Inhibitors Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Brutons Tyrosine Kinase Inhibitors pipeline landscape. It covers the Brutons Tyrosine Kinase Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Brutons Tyrosine Kinase Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline…
Smoking Cessation Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Com …
DelveInsight's, "Smoking Cessation Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Smoking Cessation pipeline landscape. It covers the Smoking Cessation Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Smoking Cessation Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in…
More Releases for Myositis
Inflammatory Myositis Market Massive Growth opportunity Ahead
Introduction
Inflammatory myositis is a group of rare autoimmune disorders characterized by chronic inflammation of skeletal muscles, leading to progressive muscle weakness, fatigue, and functional disability. The spectrum includes polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), immune-mediated necrotizing myopathy (IMNM), and overlap syndromes. These disorders can also involve other organs, most notably the lungs (interstitial lung disease), skin, heart, and joints, complicating disease management.
Historically, corticosteroids and conventional immunosuppressants have formed…
Idiopathic Inflammatory Myositis Market Growth, Trends, Consumer Demand and Key …
Introduction
Idiopathic Inflammatory Myositis (IIM) is a rare group of autoimmune muscle diseases characterized by chronic inflammation of skeletal muscles, leading to progressive weakness, fatigue, and in severe cases, disability. The group includes dermatomyositis (DM), polymyositis (PM), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), and antisynthetase syndrome. IIM can also involve systemic complications such as interstitial lung disease (ILD), cardiac dysfunction, and malignancy association, making management highly complex.
Historically, treatment relied…
Inclusion Body Myositis Market: A Guide to Understanding the Process
The global Inclusion Body Myositis (IBM) market is projected to reach approximately USD 231.4 million by 2033, growing at a CAGR of 8.7% from 2024 to 2033.
Inclusion Body Myositis Market Overview
The Inclusion Body Myositis market is growing steadily due to increasing recognition and diagnosis of this rare neuromuscular disorder. Advances in therapeutic research focusing on inflammation and muscle degeneration are driving the development of targeted treatments. Rising patient awareness and…
Myositis Clinical Trials, Pipeline Insights, and Companies 2024
DelveInsight's, "Myositis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances in Myositis Treatment…
Global Necrotizing Autoimmune Myositis Market - Opportunities & Forecasts, 2020- …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global necrotizing autoimmune myositis market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able…
Inclusion Body Myositis (IBM) - Pipeline Review And Industry Insight Report 2017
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and…
